Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) EBT Margin (2023 - 2025)

Tonix Pharmaceuticals Holding has reported EBT Margin over the past 3 years, most recently at 870.91% for Q4 2025.

  • Quarterly results put EBT Margin at 870.91% for Q4 2025, up 1054.0% from a year ago — trailing twelve months through Dec 2025 was 932.21% (up 42763.0% YoY), and the annual figure for FY2025 was 928.1%, up 43819.0%.
  • EBT Margin for Q4 2025 was 870.91% at Tonix Pharmaceuticals Holding, up from 967.66% in the prior quarter.
  • Over the last five years, EBT Margin for TNXP hit a ceiling of 561.2% in Q3 2024 and a floor of 3501.59% in Q2 2024.
  • Median EBT Margin over the past 3 years was 860.23% (2024), compared with a mean of 1083.24%.
  • Biggest five-year swings in EBT Margin: plummeted -268324bps in 2024 and later skyrocketed 213257bps in 2025.
  • Tonix Pharmaceuticals Holding's EBT Margin stood at 723.0% in 2023, then fell by -22bps to 881.45% in 2024, then rose by 1bps to 870.91% in 2025.
  • The last three reported values for EBT Margin were 870.91% (Q4 2025), 967.66% (Q3 2025), and 1369.02% (Q2 2025) per Business Quant data.